Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies

Author:

Heslop James A.1,Hammond Thomas G.2,Santeramo Ilaria3,Tort Piella Agnès1,Hopp Isabel3,Zhou Jing3,Baty Roua4,Graziano Enrique I.5,Proto Marco Bernabé5,Caron Alexis6,Sköld Patrik7,Andrews Peter W.8,Baxter Melissa A.9,Hay David C.10,Hamdam Junnat11,Sharpe Michaela E.12,Patel Sara13,Jones David R.14,Reinhardt Jens15,Danen Erik H.J.16,Ben-David Uri17,Stacey Glyn18,Björquist Petter19,Piner Jacqueline20,Mills John21,Rowe Cliff22,Pellegrini Giovanni23,Sethu Swaminathan24,Antoine Daniel J.1,Cross Michael J.1,Murray Patricia3,Williams Dominic P.25,Kitteringham Neil R.1,Goldring Chris E.P.126,Park B. Kevin1

Affiliation:

1. Medical Research Council Centre forDrug Safety Science, Division of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, U.K.

2. Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, Pharmazentrum, University of Basel, Basel, Switzerland

3. Institute of Translational Medicine, University of Liverpool, Liverpool, U.K.

4. Institute of Integrative Biology, University of Liverpool, Liverpool, U.K.

5. Laboratorios Almirall, S.A. Laurea Miro, Sant Feliu de Llobregat, Spain

6. SANOFI-Research & Development, Disposition, Safety and Animal Research, Alfortville, France

7. Uppsala Biomedicinska Centrum BMC, Husarg, Uppsala University, Uppsala, Sweden

8. Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Sheffield, U.K.

9. Developmental & Regenerative Biomedicine, School of Biomedicine, Faculty of Human and Medical Sciences, University of Manchester, Manchester, U.K.

10. Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, U.K.

11. Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

12. OakMore Solutions Ltd., Faversham, U.K.

13. ReNeuron Limited, Guildford, U.K.

14. Medicines and Healthcare Products Regulatory Agency, London, U.K.

15. Paul Ehrlich Institut, Langen, Germany

16. Faculty of Science, Leiden Academic Centre for Drug Research, Toxicology, Leiden, The Netherlands

17. Stem Cell Unit, Department of Genetics, Institute of Life Sciences, Hebrew University of Jerusalem, Givat-Ram, Jerusalem, Israel

18. U.K. Stem Cell Bank, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, U.K.

19. Cellectis AB, Göteborg, Sweden

20. GSK, David Jack Centre for Research & Development, Ware, U.K.

21. Personalised Healthcare and Biomarkers, AstraZeneca, Macclesfield, U.K.

22. CN-bio Innovations Limited, Centre for Innovation & Enterprise, Begbroke, U.K.

23. Institute of Veterinary Pathology, University of Zurich, Zurich, Switzerland

24. School of Bio Sciences & Technology and Centre for Biomaterials Science& Technology, VIT University, Vellore, India

25. Translational Safety, Drug Safety and Metabolism, AstraZeneca, Cambridge, U.K.

26. Innovative Medicines Initiative SafeSciMET, Brussels, Belgium

Abstract

Abstract The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how they may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during preclinical and clinical development of stem cell products, their utility and limitations, and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators, is likely to prove the most fruitful route to ensuring the safest possible development of new products.

Funder

Medical Research Council Centre for Drug Safety Science

United Kingdom Regenerative Medicine Platform Safety Hub

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3